The FDA said it could not approve poziotinib to treat non-small cell lung cancer, and if Spectrum wanted to resubmit an application it would need more data and a randomized study, the drugmaker said in a Nov. 28 news release. In response, Spectrum said it will deprioritize the poziotinib program, effective immediately.
The biopharmaceutical company said the 75 percent reduction in its R&D workforce will “generate the working capital required to support its strategic refocusing through 2024.”
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
